HeartBeam Enrolls First Patients in Heart Attack Detection Pilot
Event summary
- HeartBeam initiated the ALIGN-ACS pilot study on March 5, 2026, enrolling the first patients at the University Clinical Center of Serbia.
- The study aims to enroll 100 patients presenting with chest pain in emergency rooms, comparing HeartBeam’s device with standard 12-lead ECGs.
- HeartBeam received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.
- The pilot study builds on prior proof-of-concept studies suggesting HeartBeam’s 3D ECG technology can detect heart attacks with similar accuracy to standard ECGs.
The big picture
HeartBeam’s pilot study addresses a significant unmet need in cardiology: rapid, accessible heart attack detection outside of clinical settings. The company’s technology aims to reduce the ‘symptom-to-door’ time, a key driver of mortality and healthcare costs. While the market for remote cardiac monitoring is growing, HeartBeam faces the challenge of demonstrating clinical utility and securing widespread adoption among physicians and hospitals.
What we're watching
- Clinical Validation
- The success of the ALIGN-ACS pilot study is critical; failure to demonstrate efficacy relative to standard ECGs could significantly delay future FDA approval and commercialization.
- Adoption Rate
- The speed at which emergency room physicians and hospitals integrate HeartBeam’s technology into their workflows will dictate the pace of revenue generation and market penetration.
- Competitive Landscape
- The emergence of competing remote cardiac monitoring solutions or alternative diagnostic technologies could erode HeartBeam’s potential market share and pricing power.
Related topics